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Abstract     
Background 17β-estradiol (E2) has well established cardioprotective, antioxidant and 
neuroprotective role and exerts a vast range of biological effects in both sexes. Dipeptidyl 
peptidase III (DPP III) is protease involved as activator in Keap1-Nrf2 signaling pathway, 
which is important in cellular defense to oxidative and electrophilic stress. It is generally 
accepted that oxidative stress is crucial in promoting liver diseases. 
Objective To examine the effect of E2 on the expression of DPP III and heme oxygenase 1 
(HO-1) in liver of adult CBA/H mice of both sexes. 
Methods Gene and protein expression of studied enzymes were determined by quantitative 
real-time PCR and western blot analysis. Immunohistochemistry was performed to analyse 
the localisation of both proteins in different liver cell types. 
Results Ovariectomy diminished expression of DPP III and HO-1 proteins. E2 administration 
abolished this effect, and even increased these proteins above the control. A significant 
enhancement in DPP III protein was found in E2-treated males, as well. A decrease in the 
expression of HO-1, but not of the DPP III gene was detected in the liver of ovariectomized 
females. HO-1 protein was found localised in the pericentral areas of hepatic lobules (Kupffer 
cells and hepatocytes), while DPP III showed a uniform distribution within hepatic tissue. 
Conclusions We demonstrate for the first time that E2 influences the protein level of DPP III 
in vivo, and confirm earlier finding on HO-1 gene upregulation by17β-estradiol. These results 
additionally confer new insights into complexity of protective action of E2.  
 
 
Keywords: antioxidant enzyme, gene and protein expression, ovariectomy, sex-related, 
steroid hormone, zinc peptidase, immunohistochemistry 
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Introduction 
The level of oxidative damage in an organism is tightly related to development of several age-
related diseases, such as cancer, neurodegenerative diseases and diabetes [1]. The resistance 
to oxidative damage appears to be sex-related, with females being more resistant to oxidative 
damage [2]. Females show lower incidence of some age-related pathologies linked with 
oxidative stress and this sex-difference disappears after menopause, which led to conclusion 
that this protection is attributed to sex hormones. 17-β estradiol (E2) plays a key role in 
development and maintenance of normal sexual and reproductive function, and exerts a vast 
range of biological effects in the cardiovascular, immune and central nervous systems in both 
females and males [3]. E2 is a powerful endogenous antioxidant that is able to reduce lipid 
peroxidation in liver and blood [4]. Its deficiency leads to increased vascular reactive oxygen 
species (ROS) production resulting in endothelial dysfunction, while E2 replacement therapy 
can prevent these pathological changes [5]. It was shown that at physiological concentrations 
E2 does not act as an chemical antioxidant per se, due to its phenolic structure, but through 
mechanisms that involve oestrogen receptors and tyrosine kinase signalling through MAP 
kinase and NFκB [6]. Consequently, several antioxidant enzymes, including manganese 
superoxide dismutase (MnSOD) and HO-1 were shown to be up-regulated in MCF-7 cells [6]. 
Increased expression of HO-1 and several other antioxidant enzymes induced in myocardial 
cells by E2 treatment was explained by increased nuclear translocation of transcription factor 
Nrf2 [7]. HO is the rate-limiting enzyme for heme degradation in mammals. It is a stress 
response enzyme which is highly induced by variety of agents causing oxidative stress, 
hypoxia, hyperoxia, proinflammatory cytokines [8], and as such regarded as sensitive and 
reliable indicator of cellular oxidative stress. In comparison to the constitutively expressed 
HO-2, it is presumed that inducible isoform HO-1 makes greater contribution to the 
maintenance of oxidant/antioxidant homeostasis during changes in cellular environments. In 
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response to oxidative stress, HO-1 induction provides cell protection by promoting the 
catabolism of pro-oxidant metalloporphyrins to bile pigments (biliverdin and bilirubin) which 
are considered to have free radical scavenging properties [9]. As such, HO-1 acts as a potent 
antioxidant. Transcriptional control of the expression of HO-1 is mediated through the 
antioxidant response element (ARE), a transcriptional regulatory element located in the 
upstream regulatory region of many phase II enzymes that play important protective role 
against oxidative toxicity [10].  ARE is activated via translocation of Nrf2 transcription factor 
into nucleus upon oxidative stress and other stimuli. Keap1 is a substrate adaptor protein for 
the Cul3-Rbx1 E3 ubiquitin ligase complex that represses Nrf2 by targeting it for proteasomal 
degradation [11]. Most recently, it was demonstrated that cytosolic protease dipeptidyl 
peptidase III (DPP III) binds Keap1 to displace Nrf2, thus inhibiting Nrf2 ubiquitination and 
driving Nrf2-dependent transcription [12]. DPP III is a monozinc exopeptidase that 
hydrolyzes dipeptides from the N-terminal of its substrates consisting of three or more amino 
acids [13]. In mammalian tissues, it is broadly distributed and thought to contribute in the 
final steps of normal intracellular protein catabolism [14]. There are strong indications of its 
role in the endogenous pain-modulation system [15] as well as in the endogenous defense 
against oxidative stress [16]. Pathophysiological roles of human DPP III are indicated in 
cataractogenesis  [17] and malignant growth [18]. Recent studies showed that DPP III is a 
member of a six-gene signature that accurately predicts human breast cancer patient survival 
[19]. All these findings characterize human DPP III as a valuable drug target.  
Although the effect of E2 on HO-1 expression and its actions as an antioxidant have been well 
documented [6, 7], currently there are no data about the in vivo influence of E2 on sex-related 
HO-1 expression. Moreover, it is not known whether E2 influences DPP III. The liver was 
chosen, because of its high susceptibility to oxidative stress due to high metabolic activity. In 
addition, Keap1-Nrf2 pathway is indicated to counteract liver diseases. Therefore, the aim of 
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this study was to examine the effect of E2 on the expression of DPP III, the protease involved 
in Nrf2-Keap1 signaling pathway - the main pathway responsible for cell defense against 
oxidative stress [11], and to associate it with the expression of known antioxidant enzyme 
HO-1 in the liver of adult CBA/H mice of both sexes.  
Materials and methods 
Animals and experimental design   
The experiments were performed in accordance with the current laws of the Republic of 
Croatia and with the guidelines of European Community Council Directive of November 24, 
1986 (86/609/EEC). Male and female CBA/H mice aged 4 months from breeding colony of 
the Ruđer Bošković Institute (Zagreb, Croatia) were used for all experiments. The animals 
were maintained under the following laboratory conditions: three to a cage; light on from 
06:00 to 18:00; 22±2
o
C room temperature; access to food pellets, and tap water ad libitum. 
The experimental groups were as follows: male control (cm), male control treated with E2 
(cme), female sham (cf), ovariectomized (ovx), ovariectomized and treated with E2 (ovxe) 
mice. The number of animals was three per each experimental group. 
Ovariectomy procedure and E2 administration 
Ovariectomy and sham surgery were performed under ketamine/xilazyne anesthesia. Since 
low levels of E2 are normally detected in ovariectomized females due to other endogenous E2 
sources [20], plasma E2 levels were not used as indicator of efficiency of ovariectomy. 
Instead, the success of ovariectomy was checked by analysing vaginal smear during 5 
consecutive days after the surgery (data not shown). In our preliminary experiments we 
established that anestrus phase seen on vaginal smear is reflected by uterus atrophy as 
evaluated post-mortem. Body weight gain was also used as a marker of successful 
ovariectomy, since ovariectomy-induced body weight gain is established phenomena. For E2 
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administration, a pellet containing E2 (50 μg, Innovative Research of America, Sarasota, FL) 
was placed into the interscapular subcutaneous space releasing a constant dose of 830 ng 
daily. The procedure was the same for both females and males. After 37 days, animals were 
subjected to experimental protocols. 
RNA isolation and quantitative real-time PCR analysis 
Total RNA was extracted from individual mouse livers in each group using TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Reverse 
transcription and real-time PCR analysis were done as described previously [38], to quantify 
relative mRNA expression of DPP III and HO-1. Using the 2
-Ct
 method, data are presented 
as the fold-change in DPP III and HO-1 gene expression normalized to endogenous reference 
gene (β-actin) and relative to the untreated control. Assays used in this study are listed in 
Table 1. All reactions were carried out in triplicate.  
Table 1 here 
SDS-PAGE and western blotting 
Liver was homogenized with RIPA buffer supplemented with proteinase inhibitors (10% w/v) 
using an ice-jacketed Potter-Elvehjem homogenizer (1300×g). After sonification (3 x 30sec), 
whole liver homogenates were centrifuged at 16 000g for 20 min in refrigerated centrifuge. 
Supernatant was collected and total cellular proteins (100 μg per lane) were resolved by 
denaturing SDS-PAGE, transferred onto a PVDF membrane (Bio-Rad, Hercules, CA). 
Membranes were blocked in 5% nonfat dry milk in TN buffer (50mM TRIS, 150mM NaCl, 
pH=7.4) overnight, incubated with primary polyclonal rabbit antibody against DPP III 
(antiserum diluted 1:200 and incubated 3 hours at room temperature) or with primary 
polyclonal rabbit anti-mouse HO-1 antibody (Abcam, Cambridge, UK, diluted 1:200 and 
incubated 18 hours at +4°C), followed by incubation with donkey anti-rabbit IgG, horseradish 
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peroxidase-conjugated, secondary antibody (Amersham Biosciences Inc., USA) for 3 hours at 
room temperature. Equality of loading was confirmed using AmidoBlack (Sigma Aldrich, 
St.Louis, USA), which was also used for normalization of the bands [21]. The 
chemiluminescence signals were detected and analysed with the Alliance 4.7 Imaging System 
(UVITEC, Cambridge, UK). The blots were repeated at least three times and representative 
blots are presented. A high titer anti-DPP III polyclonal antibody was custom prepared by 
Abcore, USA, using purified recombinant human DPP III as antigen [22], injected into New 
Zealand white rabbits, 3-9 months old. Rabbits were bled from the auricular artery, blood was 
allowed to coagulate, clot was removed and serum was collected, clarified by centrifugation 
and stored at -20C.  
Immunohistochemistry 
After perfusion, tissue was fixed by immersion in 4% paraformaldehyde in 0.1 M PBS (pH 
7.4), then tissue blocks were embedded in paraffin, sectioned (12µm) and deparaffinised 
through a graded series of xylol and alcohols. Sections were processed with 
immunohistochemistry as previously described [23], with minor modifications. In brief, after 
incubation in 0.3% H2O2 in PBS and blocking in 5% normal goat serum to prevent 
nonspecific background staining, rabbit anti-Heme Oxygenase 1 (HO-1) monoclonal antibody 
(Abcam, UK) or anti-DPP III polyclonal antibody (custom made by Abcore, USA) was 
diluted 1:200 and incubated overnight at 4°C. Biotinylated anti-rabbit antibody from 
Vectastain ABC kit (Vector Laboratories Inc) was used according to the manufacturer’s 
protocol. For visualisation of peroxidase activity, 3,3’-diaminobenzidine tetrahydrochloride 
(DAB) with metal enhancer (CoCl2, Sigma-Aldrich) was used to produce intense gray 
staining. Sections were rinsed, air dried, dehydrated and coverslipped with Histamount 
(National Diagnostic). Negative controls were included in all immunohistochemical 
experiments by replacing the primary antibody with blocking solution, or 5% normal goat 
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serum. No immunolabeling was detected in control sections. Tissue sections were 
photographed by slide scanner NanoZoomer 2.0 (Hamamatsu) and image assembled in 
CorelDRAW(R) -Version 11.0. 
Statistical analysis  
Statistical analyses of data were performed using R v2.15.3 (CRAN, http://cran.r-project.org ) 
and RStudio for Windows, v 0.97 (http://www.rstudio.com/). For the analysis of real-time 
PCR data, all groups were tested for normality of distribution using Shapiro-Wilk test. The 
differences between multiple groups were compared with Kruskall-Wallis non-parametric 
ANOVA, followed by Wilcoxon signed-rank test for testing differences between two related 
groups. For all tests significance level was set at p < 0.05.  
Results 
DPP III gene and protein expression in the liver of CBA/H mice 
In order to establish whether sex-related differences in the basal expression of hepatic DPP III 
exist, we measured DPP III gene and protein expression in intact male and female mice. Both 
gene and protein expression levels of DPP III were found to be unchanged between sexes, as 
revealed by real-time PCR and western blot analysis (Fig. 1A, 1B). Next, we wanted to 
determine whether DPP III gene and protein expression were influenced by E2 in males, who 
basically have low levels of this hormone. Real-time PCR analysis showed no significant 
effect of E2 on DPP III gene expression in cme, compared to cm group (Figure 2A). 
However, there was a marked increase in DPP III protein level in cme, compared to cm group 
(p=0.001) (Figure 2B). We then investigated the level of DPP III gene expression in the liver 
of cf, ovx and ovxe animal group. The transcript level remained unchanged across all 
experimental groups (Figure 2C). However, western blot analysis showed that ovariectomy 
decreased DPP III protein level (p=0.048 for ovariectomized vs. control females), while E2 
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administration abolished the effect of ovariectomy and increased DPP III expression even 
higher than control level (p=0.007 for ovx vs. ovxe) (Figure 2D).  
HO-1 gene and protein expression in the liver of CBA/H mice 
The expression level of protective enzyme HO-1 in intact mice of both sexes was determined, 
since there are no such data for CBA/H strain of mice. There was no change in the hepatic 
expression of HO-1 between control animals of both sexes, as revealed by real-time PCR and 
western blot analysis (Fig. 3A, 3B). Similarly to DPP III, we wanted to determine whether 
HO-1 gene and protein expression were influenced by E2 in males. No change of expression in 
HO-1 mRNA and protein level between cm and cme group was found (Fig. 3C, 3D). 
However, real-time PCR data analysis showed significant decrease in HO-1 gene expression 
fold-change (fc = -2.85, p<0.001) in liver of ovx group compared to both cf and ovxe group 
(Figure 4A). Western blot has shown that ovariectomy decreased HO-1 protein level 
(p=0.042 for ovx vs. cf), while E2 abolished the effect of ovariectomy and increased HO-1 
expression compared with cf (p=0.002 ovx vs. ovxe) (Figure 4B). 
Immunohistochemical analysis of DPP III and HO-1 localisation in mouse liver 
Immunohistochemical analysis revealed that in the liver the expression of HO-1 was more 
pronounced in pericentral areas of hepatic lobules, and particularly in Kupffer cells, while 
DPP III protein was found to be expressed in hepatocytes and uniformly distributed 
throughout the hepatic tissue. Considering intracellular distribution, HO-1 was found more 
prominent in the cytoplasm and membranes of organelles, while strong DPP III 
immunoreactivity was detected, in addition to the cytoplasm, in nuclei and plasma membranes 
(Figure 5).  
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Discussion 
In this study the effect of E2 on DPP III and HO-1 gene and protein expression level in the 
liver of 4-month-old male and female CBA/H mice was investigated. The liver is particularly 
susceptible to oxidative stress, and E2, DPP III and HO-1 contribute to cellular antioxidant 
defense. Reactive oxygen species (ROS) are produced in the liver as byproducts of normal 
metabolism and detoxification [24].  Hepatic proteins, lipids and DNA are primarily affected 
by excessive and sustained ROS, which results in structural and functional abnormalities. The 
pathogenesis of the oxidative damage involves each hepatic cell type (i.e., hepatocytes and 
stellate cells, endothelial and Kupffer cells) [25].  It is generally accepted that oxidative stress 
plays a crucial role in promoting the progression of chronic liver diseases and hepatocellular 
carcinoma. The DPP III is involved as activator in Keap1-Nrf2-ARE signaling pathway. The 
protective roles of Nrf2 activation in the pathogenesis of liver diseases have been intensively 
investigated. In the animal model, Keap1-Nrf2-ARE pathway has been demonstrated to 
counteract non-alcoholic and alcoholic liver diseases, fibrosis and cancer, and to support liver 
regeneration [27]. Several Keap1-Nrf2-activating drugs and molecules derived from plants 
(e.g. sulforaphane) have entered clinical trials for several disease processes, in which 
oxidative stress and inflammation play a crucial role [28].  
Our present research has shown that ovariectomy markedly lowered the level of both DPP III 
and HO-1 proteins in liver tissue, and that E2 administration abolished this effect and 
increased DPP III and HO-1 protein expression in both sexes. By using 
immunohistochemistry, we identified that HO-1 localises in the pericentral areas of hepatic 
lobules, praticularly in Kupffer cells, which is in accordance to previous studies [26]. In our 
knowledge, the present study is the first to have analysed the immunohistochemical 
localisation of DPP III in the mouse liver. In contrast to HO-1 protein, we have found a 
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uniform expression of DPP III within hepatic tissue, with a more intense signal in nuclei and 
membranes of hepatocytes. Interestingly, human DPP III protein is localised in the cytoplasm, 
plasma membranes and nuclei of cells (http://www.proteinatlas.org/).  
Our present data clearly show for the first time that E2 influences the level of DPP III protein 
in mice of both sexes. It seems that E2 affects DPP III at a post-transcriptional level. This is in 
accordance with up to date knowledge on DPP III gene expression, since no estrogen response 
element was recognized in its gene promoter, and transcription factors Ets-1/Elk-1 and 
C/EBP-β have been experimentally confirmed as relevant for human DPP III gene regulation 
[29, 30]. Human and mouse DPP III share 93 % of amino acid sequence identity. Mouse DPP 
III (protein) has not been characterized yet biochemically, while human and rat orthologs 
have been the subject of intensive investigation [13, 14, 29-31]. The increased level of DPP 
III protein observed in this study as a result of E2 action in vivo could be related to an 
imbalance between protein synthesis and degradation, i.e. it could be due to a decreased 
proteolytic degradation in E2-treated animals. It is known that E2 regulates several mammalian 
peptidases, such as neprilysin, cathepsin D and ubiquitin specific peptidase 19 (USP 19) [32-
33]. Ogawa and colleagues have shown that E2 increases the expression of USP 19 in mouse 
myoblasts and satellite cells, both in vitro and in vivo [34]. As USP 19 does not associate with 
proteasome, it may release ubiquitin from specific proteins and may have regulatory function, 
since removal of ubiquitin chain from specific substrate proteins inhibits their degradation by 
proteasome. At this point, it is not known whether the DPP III is among substrates of USP 19 
or some other deubiquitinating enzyme. However, several ubiquitination sites can be 
predicted in DPP III molecule, and experimental evidence on human DPP III ubiquitination 
has been reported [36].  
Considering that males have lower serum E2 levels compared to intact females, and our 
finding that E2 administration increases the DPP III protein content, the observed lack of 
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difference in protein DPP III expression in intact male and female mice is intriguing. This 
indicates that in vivo the regulation of DPP III protein is rather complex, and that the 
existence of other factors (which are able to up-regulate DPP III) can be postulated. We can 
speculate that in male mice, androgens could up-regulate DPP III protein. However, up to date 
there are no data about the effect of testosterone or any other androgenic hormone on the 
regulation of DPP III. 
      Our results on the increased expression of HO-1 gene are in agreement with findings of 
Yu et al, [7] about E2 effects of transcription factor Nrf2 on myocardial cells. These authors 
have shown a concomitant upregulation of the transcription factor Nrf2 in nuclear extracts. 
Moreover, since HO-1 is one of the phase II enzymes with ARE in its promoter, and DPP III 
was shown to compete with Nrf2 for binding to the same site on cytosolic repressor Keap1, 
our finding of an estrogen-induced increase in HO-1 mRNA and protein content is consistent 
with the notion that enhanced DPP III protein releases Nrf2 from its repressor and thereby 
augments the transcription of responsive genes, such as HO-1. E2 has well-established 
cytoprotective effect during oxidative stress and its depletion contributes to the pathogenesis 
of some age-related diseases [37]. We have previously demonstrated that the resistance to 
hyperoxia-induced oxidative stress appears to be female-biased [38, 39] and that E2 deficiency 
caused an increase in oxidative damage in females exposed to hyperoxia, while E2 
administration abolished this effect. Moreover, E2 treatment significantly decreased oxidative 
damage in males [40]. These results strongly suggested a beneficial effect of E2 in resistance 
to oxidative stress. Data from our present study clearly show that protein levels of two 
enzymes involved in endogenous response to oxidative stress, DPP III and HO-1, are 
increased upon administration of E2 in mice.   
Although gender-specific differences in hepatic HO expression and activity have been shown 
in previous studies [41] here we demonstrate for the first time that E2 influences the protein 
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level of DPP III in vivo. These results additionally confer new insights into the complexity of 
the protective action of this hormone, and in its relationship to Keap1-Nrf2-ARE pathway, 
which contains molecular targets potentially able to prevent and treat liver diseases.
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Legends to figures 
Figure 1. DPP III expression in liver of control CBA/H mice. Real-time PCR analysis of 
DPP III gene expression in liver of control male (cm) and female (cf) CBA/H mice. Fold-
change in gene expression was calculated with 2
–ΔΔCT
 method, using β-actin as endogenous 
control (A). Western blot analysis of DPP III protein expression in liver of control male and 
female CBA/H mice. Bands are normalized by using AmidoBlack (B). All data are mean ± 
SD from 3 individual mice per group.  
Figure 2. Effect of E2 on DPP III expression in liver of CBA/H mice. Real-time PCR 
analysis of DPP III gene expression in liver of control (cm) and E2-treated male (cme) CBA/H 
mice (A), and sham (cf), ovariectomized (ovx) and ovariectomized females treated with E2 
(ovxe) (C). Fold-change in gene expression was calculated with 2
–ΔΔCT
 method, using β-actin 
as endogenous control. Western blot analysis of DPP III protein level in liver of control and 
E2-treated male CBA/H mice (B: p=0.001 control vs. E2-treated group) and sham, 
ovariectomized, and ovariectomized females treated with E2 (D:  p=0.048 control vs. 
ovariectomized; p=0.007 ovariectomized vs. ovariectomized treated with E2). Bands are 
normalized by using AmidoBlack. All data are mean ± SD from 3 individual mice per group.  
Figure 3. HO-1 expression in liver of CBA/H mice. Real-time PCR analysis of HO-1 gene 
expression in liver of control male (cm) and female (cf) CBA/H mice (A), and  in control 
(cm) and E2-treated male (cme) CBA/H mice (C). Fold-change in gene expression was 
calculated with 2
–ΔΔCT
 method, using β-actin as endogenous control. Western blot analysis of 
HO-1 protein expression in liver of control male (cm) and female (cf) CBA/H mice (B),  and 
control male (cm) and E2-treated male (cme) CBA/H mice (D). Bands are normalized by 
using AmidoBlack. All data are mean ± SD from 3 individual mice per group. 
Figure 4. Effect of E2 on HO-1 expression in liver of CBA/H mice. Real-time PCR analysis 
of HO-1 gene expression in liver of sham (cf), ovariectomized (ovx) and ovariectomized 
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treated with E2 (ovxe); p<0.001 cf vs. ovx and ovx vs. ovxe. Fold-change in gene expression 
was calculated with 2
–ΔΔCT
 method, using β-actin as endogenous control (A). Western blot 
analysis of HO-1 protein expression in liver of sham (cf), ovariectomized (ovx) and 
ovariectomized females treated with E2 (ovxe); p=0.042 control vs. ovariectomized; p=0.002 
ovariectomized vs. ovariectomized treated with E2 (B). Bands are normalized by using 
AmidoBlack.  All data are mean ± SD from 3 individual mice per group. 
Figure 5. Immunohistochemical localisation of HO-1 and DPP III protein in mouse liver. (A) 
Negative control (liver tissue not incubated with primary antibody). (B) HO-1 
immunoreactivity is more pronounced in pericentral areas, inside Kupffer cells (arrows), and 
in hepatocytes (H). (C) DPP III immunoreactivity is localised in hepatocytes (H) and 
uniformly distributed throughout the hepatic tissue. 
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Table 1. Probes used for quantitative real-time PCR analysis. 
 
 
Gene Assay ID Product size (bp) 
β-actin Mm00607939_s1 115 
dipeptidyl peptidase III Mm00505462_m1 89 
heme oxygenase 1  Mm00516007_m1 92 
Table 1
Click here to download Table: Table_JENI.docx 
